About UCSF Search UCSF UCSF Medical Center

James D. Marks, MD, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
marks_james

Professor, Departments of Anesthesia and Pharmaceutical Chemistry, UCSF

marksj@anesthesia.ucsf.edu

Phone: (415) 206-3256 (voice), 206-8145 (Asst)
SFGH 3C-38, San Francisco, CA 94143

View on UCSF Profiles


Education

University of California, Berkeley, Biochemistry
University of California, San Francisco, M.D., 1979, Medicine
Medical Research Council, Laboratory of Molecular Biology, Cambridge, England, Ph.D., 1992, Molecular Biology

Professional Experience

  • 1979-1982
    Residency in Internal Medicine, University of California, San Francisco
  • 1982-1983
    Fellowship in Critical Care Medicine, University of California, San Francisco
  • 1983-1984
    Assistant Professor of Medicine, University of California, San Francisco
  • 1984-1986
    Residency in Anesthesia, University of California, San Francisco
  • 1986-1989
    Assistant Professor of Anesthesia and Medicine, University of California, San Francisco
  • 1992-1994
    Assistant Professor of Anesthesia and Pharmaceutical Chemistry;
  • 1994-1998
    Associate Professor of Anesthesia and Pharmaceutical Chemistry
  • 1997-present
    Director, Medical-Surgical Intensive Care Unit, San Francisco General Hospital
  • 1998-present
    Professor of Anesthesia and Pharmaceutical Chemistry

Honors & Awards

  • (1975)
    Phi Beta Kappa
  • (1979)
    Alpha Omega Alpha
  • (1994)
    Beckman Young Investigator Award
  • (1995, 1996)
    CaPCURE Research Award

Selected Publications

  1. Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL. Selective Targeting of TGF-ß Activation to Treat Fibroinflammatory Airway Disease. Sci Transl Med. 2014 Jun 18; 6(241):241ra79.
    View on PubMed
  2. Jones AR, Stutz CC, Zhou Y, Marks JD, Shusta EV. Identifying blood-brain-barrier selective single-chain antibody fragments. Biotechnol J. 2014 May; 9(5):664-74.
    View on PubMed
  3. Strotmeier J, Mahrhold S, Krez N, Janzen C, Lou J, Marks JD, Binz T, Rummel A. Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A. FEBS Lett. 2014 Apr 2; 588(7):1087-93.
    View on PubMed
  4. Janardhanan P, Mello CM, Singh BR, Lou J, Marks JD, Cai S. RNA aptasensor for rapid detection of natively folded type A botulinum neurotoxin. Talanta. 2013 Dec 15; 117:273-80.
    View on PubMed
  5. Mahrhold S, Strotmeier J, Garcia-Rodriguez C, Lou J, Marks JD, Rummel A, Binz T. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013 Jul 1; 453(1):37-47.
    View on PubMed
  6. Jones RG, Marks JD. Use of a new functional dual coating (FDC) assay to measure low toxin levels in serum and food samples following an outbreak of human botulism. J Med Microbiol. 2013 Jun; 62(Pt 6):828-35.
    View on PubMed
  7. Federman N, Chan J, Nagy JO, Landaw EM, McCabe K, Wu AM, Triche T, Kang H, Liu B, Marks JD, Denny CT. Enhanced growth inhibition of osteosarcoma by cytotoxic polymerized liposomal nanoparticles targeting the alcam cell surface receptor. Sarcoma. 2012; 2012:126906.
    View on PubMed
  8. Zhang Y, Lou J, Jenko KL, Marks JD, Varnum SM. Simultaneous and sensitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem. 2012 Nov 15; 430(2):185-92.
    View on PubMed
  9. Meng Q, Garcia-Rodriguez C, Manzanarez G, Silberg MA, Conrad F, Bettencourt J, Pan X, Breece T, To R, Li M, Lee D, Thorner L, Tomic MT, Marks JD. Engineered domain-based assays to identify individual antibodies in oligoclonal combinations targeting the same protein. Anal Biochem. 2012 Nov 15; 430(2):141-50.
    View on PubMed
  10. Carrico ZM, Farkas ME, Zhou Y, Hsiao SC, Marks JD, Chokhawala H, Clark DS, Francis MB. N-Terminal labeling of filamentous phage to create cancer marker imaging agents. ACS Nano. 2012 Aug 28; 6(8):6675-80.
    View on PubMed
  11. McCabe KE, Liu B, Marks JD, Tomlinson JS, Wu H, Wu AM. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012 Jun; 14(3):336-47.
    View on PubMed
  12. Zhou Y, Zhao L, Marks JD. Selection and characterization of cell binding and internalizing phage antibodies. Arch Biochem Biophys. 2012 Oct 15; 526(2):107-13.
    View on PubMed
  13. Zhou Y, Goenaga AL, Harms BD, Zou H, Lou J, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. Mol Cancer Ther. 2012 Jul; 11(7):1467-76.
    View on PubMed
  14. Liu YY, Rigsby P, Sesardic D, Marks JD, Jones RG. A functional dual-coated (FDC) microtiter plate method to replace the botulinum toxin LD50 test. Anal Biochem. 2012 Jun 1; 425(1):28-35.
    View on PubMed
  15. Kirpotin DB, Noble CO, Hayes ME, Huang Z, Kornaga T, Zhou Y, Nielsen UB, Marks JD, Drummond DC. Building and characterizing antibody-targeted lipidic nanotherapeutics. Methods Enzymol. 2012; 502:139-66.
    View on PubMed
  16. Zhou Y, Marks JD. Discovery of internalizing antibodies to tumor antigens from phage libraries. Methods Enzymol. 2012; 502:43-66.
    View on PubMed
  17. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP, Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012 Jan; 11(1):143-53.
    View on PubMed
  18. Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem. 2011; 12:58.
    View on PubMed
  19. Wang Y, Keck ZY, Saha A, Xia J, Conrad F, Lou J, Eckart M, Marks JD, Foung SK. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. J Biol Chem. 2011 Dec 23; 286(51):44218-33.
    View on PubMed
  20. Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15; 421(2):351-61.
    View on PubMed

Go to UCSF Profiles, powered by CTSI